A large-scale organoid-based screening platform to advance drug repurposing in pancreatic cancer

Sara Mainardi; Rene Bernards

Cell Genomics (Feb 2022)

A large-scale organoid-based screening platform to advance drug repurposing in pancreatic cancer

Sara Mainardi,
Rene Bernards

Affiliations

Sara Mainardi: Division of Molecular Carcinogenesis, Oncode Institute, the Netherlands Cancer Institute, Amsterdam, the Netherlands; Corresponding author
Rene Bernards: Division of Molecular Carcinogenesis, Oncode Institute, the Netherlands Cancer Institute, Amsterdam, the Netherlands

Journal volume & issue: Vol. 2, no. 2
p. 100100

Abstract

Read online

Hirt et al.1 report an automated, high-throughput drug screening platform for organoid cultures to enable repurposing of previously approved drugs for pancreatic cancers harboring specific genetic alterations. The pancreatic cancer organoid biobank also represents a valuable tool to uncover new drug-gene interactions in pancreatic tumors.

Published in Cell Genomics

ISSN: 2666-979X (Online)
Publisher: Elsevier
Country of publisher: United States
LCC subjects: Science: Biology (General): Genetics; Medicine: Internal medicine
Website: https://www.cell.com/cell-genomics/home

About the journal